Thiazolidinediones inhibit the progression of established hypertension in the Dahl salt-sensitive rat

Diabetes and Vascular Disease Research

Volumn 4, Issue 2, 2007, Pages 117-123

  Bolten, Charles W ^a   Payne, Maria A ^a   Mcdonald, William G ^a   Blanner, Patrick M ^a   Chott, Robert C ^a   Ghosh, Sarbani ^a   Arhancet, Graciela B ^a   Staten, Nicholas R ^a   Gulve, Eric A ^a   Sullivan, Patrick M ^a   Hromockyj, Alexander E ^a   Colca, Jerry R ^b  

^a PFIZER INC   (United States)

^b Kalamazoo Metabolic Research   (United States)

Author keywords

Dahl rats; Insulin resistance; Metabolic hypertension; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; AMLODIPINE; CARBOXYMETHYLCELLULOSE; FATTY ACID; GLUCOSE; INSULIN; INTERLEUKIN 8; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PNU 91325; ROSIGLITAZONE; SODIUM CHANNEL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFECT; HYPERTENSION; LIPID BLOOD LEVEL; MALE; METABOLIC REGULATION; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; TELEMETRY;

ADIPONECTIN; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART RATE; HYPERTENSION; INSULIN; LIPIDS; MALE; PPAR GAMMA; PYRIDINES; RATS; RATS, INBRED DAHL; SODIUM CHLORIDE, DIETARY; THIAZOLIDINEDIONES;

EID: 34547450518     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.029     Document Type: Article

References (31)

1. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999;16:179-92.
2. Stumvoll M, Haring H. Insulin resistance and insulin sensitizers. Hormone Research 2001;55(suppl 2):3-13.
3. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992;15:1075-8.
4. Komers R, Vrana A. Thiazolidinediones - tools for the research of metabolic syndrome X. Physiol Res 1998;47:215-25.
5. Owens DR. Thiazolidinediones: a pharmacological overview. Clin Drug Invest 2002;22:485-505.
6. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol 1993;265:R726-R732.
7. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-8.
8. Gerber P, Lubben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003;19:532-9.
9. Zhang HY, Reddy SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 1994;24:106-10.
10. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999;48:1448-53.
11. Olefsky JM, Saltiel AR. PPAR gamma and the treatment of insulin resistance. Trend Endocrinol Metab 2000;11:362-8.
12. Willson T, Cobb JE, Cowan DJ et al. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-8.
13. Matsusue K, Haluzik M, Lambert G et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003;111:737-47.
14. He W, Barak Y, Hevener A et al. Adipose specific peroxisome proliferators-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003;100:15712-17.
15. Zhang J, Fu M, Cui T et al. Selective disruption of PPAR2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 2004;101:10703-08.
16. Norris AW, Chen L, Fisher SJ et al. Muscle-specific PPAR-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003;112:608-18.
17. Colca JR, McDonald WG, Waldon DL et al. Identification of a novel mitochondrial protein ('mitoNEET') cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol 2004;286:E252-E260.
18. Feinstein DL, Spagnolo A, Akar C et al. Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key? Biochem Pharmacol 2005;170:177-88.
19. Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005;102:9406-11.
20. Guan Y, Hao C, Cha DR et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nature Medicine 2005;11:861-6.
21. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARγ). J Biol Chem 1995;270:12953-6.
22. Bolten CW, Blanner PM, McDonald WG et al. Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPARγ. Gene Regulation and Systems Biolog 2007; in press.
23. Harrigan GG, Colca JR, Szalma S, Boros LG. PNU-91325 increases fatty acid synthesis from glucose and mitochondrial long chain fatty acid degradation: a comparative tracer-based metabolomics study with rosiglitazone and pioglitazone in HepG2 cells. Metabolomics 2006;2:21-9.
24. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol 2005;5:129-34.
25. Maeda N, Takahashi M, Funahashi T et al. PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001;50:2094-9.
26. Yu JG, Javorschi S, Hevener AL et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-74.
27. Cox PJ, Ryan DA, Hollis FJ et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer in humans. Drug Metabolism and Disposition 2000;28:772-80.
28. Kim F, Tysseling KA, Rice J et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKβ. Arterioscler Thromb Vasc Biol 2005;25:989-94.
29. Colca JR. Insulin sensitizers may prevent metabolic inflammation. Biochem Pharmacol 2006;72:125-31.
30. Bagi Z, Koller A, Kaley G. PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol 2003;286:H742-H748.
31. Wiley SE, Murphy AN, Ross SA, van der Geer P, Dixon JE. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. PNAS published March 21, 2007, 10.1073/pnas.0701078104.